To The Moon

$TransMedics Group, Inc.(TMDX)$

TransMedics recently faced a short-seller report unlike any typical critique—it came with a $0 price target. Yes, you read that right: the short-seller is claiming the company is essentially worthless, branding it a complete fraud. While other reports often suggest a stock could lose 50-70% of its value, this bold claim of a zero-dollar valuation is unprecedented in my experience.

Initially, TransMedics' stock reacted sharply, dropping nearly 17% within the first hour of trading but managed to recover throughout the day, closing down by just 5.16%. This rebound suggests that the market might have deemed the report exaggerated or unfounded. However, the language and accusations in the report were undeniably severe.

The short-seller alleged that TransMedics is engaged in unethical and illegal activities, including extortion, racketeering, and organ trafficking, disguised as a legitimate medical device company. They also claimed that the company pressures surgeons to use potentially unsafe organs, which could jeopardize patient safety, leading to dissatisfaction among transplant centers. Other accusations included device failures, high costs, aggressive sales tactics, and transparency issues, alongside significant competition from newer technologies.

Regulatory scrutiny was also highlighted, with potential investigations from agencies like the FDA, DOJ, and IRS being mentioned. The report painted a picture of inexperienced staff, unlicensed surgeons, and poor patient outcomes. It even criticized the CEO's demeanor, calling him arrogant and the company dishonest. There were references to the CEO arriving at conferences with a "secret-service-style" entourage, which seemed more like an attempt to sensationalize than to provide substantive criticism.

While the report was lengthy—spanning over 340 pages—it leaned heavily on dramatic language and aggressive accusations, which raises questions about its intent and credibility. Why would a well-supported counterargument require so much length and hyperbole? The claims of incompetence and unethical practices, if true, would naturally harm the company’s reputation and operations. But the idea that TransMedics would deliberately compromise its own success seems counterintuitive.

Despite the drama, the company remains positioned for growth. It has a market cap of $2.31 billion and, while the stock has declined significantly (50% in the last three months, 53.4% in six months), analysts still project substantial year-over-year growth. For fiscal 2025, sales are expected to grow by 21.4%, though this is a step down from the 77% growth anticipated for fiscal 2024. Analysts also predict improvements in EPS and revenue for the next quarter.

In summary, while the short-seller's allegations are serious, their tone and presentation may undermine the credibility of their claims. Investors will need to weigh the evidence and the company's fundamentals before drawing conclusions. As for my personal stake, I hold no in TransMedics, and while the report hasn’t helped, I remain skeptical of its extreme assertions.

It was the first time we saw a decline quarter-over-quarter, something the short-seller report also highlighted. Let’s address that in a moment. However, it's clear that the language used in the report was crafted to manipulate perceptions.

Take, for instance, the discussion around Medicare and reimbursements. The CEO clarified on a 2023 call that organ transplant logistics, including aviation and transport, are fully reimbursed through organ acquisition mechanisms, with no set limits. This is critical context often omitted or distorted in critiques. When asked about revenue from aviation services, the CEO emphasized this: aviation is not a profit center but a necessary, fully reimbursed service integral to organ transplantation logistics. If reimbursement mechanisms exist to support these processes, why wouldn’t the company utilize them? It’s standard practice in any industry to leverage such programs.

The short-seller report also ridicules TransMedics for owning planes. However, having in-house aviation supports smoother operations and better cost control, which addresses issues like the hit to margins last quarter due to reliance on third-party planes for maintenance. While operating planes entails upfront costs for training, maintenance, and infrastructure, the long-term benefits include more efficient operations.

Interestingly, the report calls TransMedics “an airline with a medical device attached,” citing a lofty revenue multiple of seven times trailing twelve-month sales. However, that figure aligns with a company growing at 77% year-over-year. The report also claims product sales are "tanking sequentially," which is misleading. While there was a slight decline quarter-over-quarter, calling it a "tank" is an exaggeration. The company is still positioned for substantial growth, with fiscal 2025 expected to turn free cash flow positive, generating $19.6 million and growing to $98.4 million in fiscal 2026—a projected year-over-year growth of over 400%.

Short-seller reports are often designed to be dramatic and sensational to maximize their impact, as the authors stand to profit from a stock’s immediate decline. This was evident here, with TransMedics’ stock initially plunging at the start of the day before recovering significantly, closing above its 20-day moving average by the end of the week. While it briefly surpassed the 50-day moving average earlier, it didn’t sustain that level. Nevertheless, the recovery underscores the market's skepticism toward the report's claims.

Short reports are ostensibly meant to challenge bullish theses, and occasionally they raise valid concerns. However, many rely on manipulation and over-the-top rhetoric to achieve their aims. A strong counterargument doesn’t need 342 pages of aggressive language to make its point. For now, I didn’t buy the dip, as I want to see renewed growth and further guidance for 2025 before start my position.

Conclusion

Lastly, while the CEO’s personality—described as peculiar and aggressive during earnings calls and conferences—might rub some people the wrong way, that’s no justification for the extreme language used in this report. He’s made bold claims about the company’s potential, such as reaching 10,000 cases by 2028. If the market and opportunities are as large as stated, seasonal excuses won’t hold up quarter after quarter. Let’s see what the next earnings report reveals.

@Daily_Discussion @TigerPM @TigerObserver @Tiger_comments @TigerClub